Asset

Buntanetap

Annovis Bio Inc. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (5)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT05686044phase2_3completed2023-04-012024-02-13Annovis Bio Inc.A Dose-ranging Study to Investigate Efficacy of Buntanetap in Mild to Moderate AD
NCT06709014phase3active_not_recruiting2025-02-042027-12-01Annovis Bio Inc.A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD
NCT05357989phase3completed2022-08-032023-12-04Annovis Bio Inc.A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
NCT07284784phase2_3recruiting2026-01-092029-09-01Annovis Bio Inc.A Study of Buntanetap in Participants With PD
NCT07757204phase2_3not_yet_recruiting2026-09-212030-02-21Annovis Bio Inc.An Open-label Long-term Safety Study of Buntanetap in Participants With AD

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)